Arcutis Biotherapeutics is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. Co.'s product candidate, topical roflumilast cream, is used for plaque psoriasis, including intertriginous psoriasis, as well as atopic dermatitis. Co. is developing a topical foam formulation of roflumilast for the treatment of scalp psoriasis and seborrheic dermatitis; ARQ-252, a topical cream formulation of a small molecule inhibitor of Janus kinase type 1 for chronic hand eczema and vitiligo; and ARQ-255, an alternative topical formulation of ARQ-252 designed to reach into the skin in order to treat alopecia areata.

ARQT SEC Filing Email Alerts Service